Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
A Comprehensive Review of Lomustine's R&D Innovations and Drug Target Mechanism
21 September 2023
This article summarized the latest R&D progress of Lomustine, the Mechanism of Action for Lomustine, and the drug target R&D trends for Lomustine.
Advanced Tech.
7 min read
Medications intervening from the root of difficult and complex diseases: Oligonucleotides
21 September 2023
Oligonucleotides (ONs) are a class of drugs composed of single or double strands of oligonucleotides synthesized by artificial chemistry.
Drug Insights
5 min read
Pharmaceutical Insights: Vorinostat's R&D Progress and its Mechanism of Action on Drug Target
21 September 2023
This article summarized the latest R&D progress of Vorinostat, the Mechanism of Action for Vorinostat, and the drug target R&D trends for Vorinostat.
Latest Hotspot
3 min read
Yescarta® Car T-cell therapy from Kite greatly boosts treatment response and prolongs remission in relapsed/resistant Large B-cell Lymphoma patients
21 September 2023
Kite's Car T-cell Therapy Yescarta® exhibits a substantial treatment response rate and durable remission for patients with relapsed/resistant Large B-cell Lymphoma.
Drug Insights
4 min read
Exploring Voclosporin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
21 September 2023
This article summarized the latest R&D progress of Voclosporin, the Mechanism of Action for Voclosporin, and the drug target R&D trends for Voclosporin.
Valuable Targets
8 min read
Analysis on the Clinical Research Progress of CTLA-4 Inhibitors
21 September 2023
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), also known as CD152, is a transmembrane protein on the surface of T cells encoded by the CTLA-4 gene.
Drug Insights
4 min read
Decoding Vismodegib: A Comprehensive Study of its R&D Trends
21 September 2023
This article summarized the latest R&D progress of Vismodegib, the Mechanism of Action for Vismodegib, and the drug target R&D trends for Vismodegib.
Latest Hotspot
3 min read
Vividion Therapeutics initiates the phase I clinical trial in advanced solid tumors utilizing KEAP1 activator
21 September 2023
Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.
Drug Insights
4 min read
Deep Scientific Insights on Vildagliptin's R&D Progress, Mechanism of Action, and Drug Target
21 September 2023
This article summarized the latest R&D progress of Vildagliptin, the Mechanism of Action for Vildagliptin, and the drug target R&D trends for Vildagliptin.
Valuable Targets
4 min read
Review and Prospects of CYP1A2 Inhibitors
21 September 2023
Recombinant Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1A subfamily of the CYP1 family and is encoded by the CYP1A2 gene.
Drug Insights
5 min read
An In-depth Analysis of Sotagliflozin's R&D Progress and Mechanism of Action on Drug Target
21 September 2023
This article summarized the latest R&D progress of Sotagliflozin, the Mechanism of Action for Sotagliflozin, and the drug target R&D trends for Sotagliflozin.
Latest Hotspot
3 min read
The first patient receives treatment from NeuroBo Pharmaceuticals in their Phase 2a Clinical Trial studying DA-1241
21 September 2023
NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.